The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Antidiabetic Biguanides-Global Market Insights and Sales Trends 2024
Synopsis
The global Antidiabetic Biguanides market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of Antidiabetic Biguanides in various end use industries. The expanding demands from the Hospitals, Clinics and Other, are propelling Antidiabetic Biguanides market. Metformin IR, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Metformin SR segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by manufacturers, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Antidiabetic Biguanides, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Antidiabetic Biguanides market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Antidiabetic Biguanides market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Antidiabetic Biguanides sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Antidiabetic Biguanides covered in this report include Pfizer, AstraZeneca, GlaxoSmithKline, Merck & Co, Eli Lilly, Sanofi, Takeda Pharmaceuticals, Novo Nordisk and Servier Laboratories, etc.
The global Antidiabetic Biguanides market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Pfizer
AstraZeneca
GlaxoSmithKline
Merck & Co
Eli Lilly
Sanofi
Takeda Pharmaceuticals
Novo Nordisk
Servier Laboratories
Boehringer Ingelheim
Bristol-Myers Squibb
Global Antidiabetic Biguanides market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Antidiabetic Biguanides market, Segment by Type:
Metformin IR
Metformin SR
Global Antidiabetic Biguanides market, by Application
Hospitals
Clinics
Other
Core Chapters
Chapter One: Introduces the study scope of this report, executive summary of market segments by Type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Two: Detailed analysis of Antidiabetic Biguanides manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Three: Sales, revenue of Antidiabetic Biguanides in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.
Chapter Four: Introduces market segments by Application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Five, Six, Seven, Eight and Nine: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.
Chapter Ten: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter Eleven: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics. Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Analysis of sales channel, distributors and customers.
Chapter Thirteen: Research Findings and Conclusion.
The global Antidiabetic Biguanides market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of Antidiabetic Biguanides in various end use industries. The expanding demands from the Hospitals, Clinics and Other, are propelling Antidiabetic Biguanides market. Metformin IR, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Metformin SR segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by manufacturers, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Antidiabetic Biguanides, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Antidiabetic Biguanides market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Antidiabetic Biguanides market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Antidiabetic Biguanides sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Antidiabetic Biguanides covered in this report include Pfizer, AstraZeneca, GlaxoSmithKline, Merck & Co, Eli Lilly, Sanofi, Takeda Pharmaceuticals, Novo Nordisk and Servier Laboratories, etc.
The global Antidiabetic Biguanides market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Pfizer
AstraZeneca
GlaxoSmithKline
Merck & Co
Eli Lilly
Sanofi
Takeda Pharmaceuticals
Novo Nordisk
Servier Laboratories
Boehringer Ingelheim
Bristol-Myers Squibb
Global Antidiabetic Biguanides market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Antidiabetic Biguanides market, Segment by Type:
Metformin IR
Metformin SR
Global Antidiabetic Biguanides market, by Application
Hospitals
Clinics
Other
Core Chapters
Chapter One: Introduces the study scope of this report, executive summary of market segments by Type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Two: Detailed analysis of Antidiabetic Biguanides manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Three: Sales, revenue of Antidiabetic Biguanides in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.
Chapter Four: Introduces market segments by Application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Five, Six, Seven, Eight and Nine: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.
Chapter Ten: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter Eleven: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics. Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Analysis of sales channel, distributors and customers.
Chapter Thirteen: Research Findings and Conclusion.
Index1 Antidiabetic Biguanides Market Overview
1.1 Antidiabetic Biguanides Product Overview
1.2 Antidiabetic Biguanides Market Segment by Type
1.2.1 Metformin IR
1.2.2 Metformin SR
1.3 Global Antidiabetic Biguanides Market Size by Type
1.3.1 Global Antidiabetic Biguanides Market Size Overview by Type (2018-2029)
1.3.2 Global Antidiabetic Biguanides Historic Market Size Review by Type (2018-2023)
1.3.3 Global Antidiabetic Biguanides Forecasted Market Size by Type (2024-2029)
1.4 Key Regions Market Size Segment by Type
1.4.1 North America Antidiabetic Biguanides Sales Breakdown by Type (2018-2023)
1.4.2 Europe Antidiabetic Biguanides Sales Breakdown by Type (2018-2023)
1.4.3 Asia-Pacific Antidiabetic Biguanides Sales Breakdown by Type (2018-2023)
1.4.4 Latin America Antidiabetic Biguanides Sales Breakdown by Type (2018-2023)
1.4.5 Middle East and Africa Antidiabetic Biguanides Sales Breakdown by Type (2018-2023)
2 Global Antidiabetic Biguanides Market Competition by Company
2.1 Global Top Players by Antidiabetic Biguanides Sales (2018-2023)
2.2 Global Top Players by Antidiabetic Biguanides Revenue (2018-2023)
2.3 Global Top Players by Antidiabetic Biguanides Price (2018-2023)
2.4 Global Top Manufacturers Antidiabetic Biguanides Manufacturing Base Distribution, Sales Area, Product Type
2.5 Antidiabetic Biguanides Market Competitive Situation and Trends
2.5.1 Antidiabetic Biguanides Market Concentration Rate (2018-2023)
2.5.2 Global 5 and 10 Largest Manufacturers by Antidiabetic Biguanides Sales and Revenue in 2022
2.6 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Antidiabetic Biguanides as of 2022)
2.7 Date of Key Manufacturers Enter into Antidiabetic Biguanides Market
2.8 Key Manufacturers Antidiabetic Biguanides Product Offered
2.9 Mergers & Acquisitions, Expansion
3 Antidiabetic Biguanides Status and Outlook by Region
3.1 Global Antidiabetic Biguanides Market Size and CAGR by Region: 2018 VS 2022 VS 2029
3.2 Global Antidiabetic Biguanides Historic Market Size by Region
3.2.1 Global Antidiabetic Biguanides Sales in Volume by Region (2018-2023)
3.2.2 Global Antidiabetic Biguanides Sales in Value by Region (2018-2023)
3.2.3 Global Antidiabetic Biguanides Sales (Volume & Value) Price and Gross Margin (2018-2023)
3.3 Global Antidiabetic Biguanides Forecasted Market Size by Region
3.3.1 Global Antidiabetic Biguanides Sales in Volume by Region (2024-2029)
3.3.2 Global Antidiabetic Biguanides Sales in Value by Region (2024-2029)
3.3.3 Global Antidiabetic Biguanides Sales (Volume & Value), Price and Gross Margin (2024-2029)
4 Global Antidiabetic Biguanides by Application
4.1 Antidiabetic Biguanides Market Segment by Application
4.1.1 Hospitals
4.1.2 Clinics
4.1.3 Other
4.2 Global Antidiabetic Biguanides Market Size by Application
4.2.1 Global Antidiabetic Biguanides Market Size Overview by Application (2018-2029)
4.2.2 Global Antidiabetic Biguanides Historic Market Size Review by Application (2018-2023)
4.2.3 Global Antidiabetic Biguanides Forecasted Market Size by Application (2024-2029)
4.3 Key Regions Market Size Segment by Application
4.3.1 North America Antidiabetic Biguanides Sales Breakdown by Application (2018-2023)
4.3.2 Europe Antidiabetic Biguanides Sales Breakdown by Application (2018-2023)
4.3.3 Asia-Pacific Antidiabetic Biguanides Sales Breakdown by Application (2018-2023)
4.3.4 Latin America Antidiabetic Biguanides Sales Breakdown by Application (2018-2023)
4.3.5 Middle East and Africa Antidiabetic Biguanides Sales Breakdown by Application (2018-2023)
5 North America Antidiabetic Biguanides by Country
5.1 North America Antidiabetic Biguanides Historic Market Size by Country
5.1.1 North America Antidiabetic Biguanides Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
5.1.2 North America Antidiabetic Biguanides Sales in Volume by Country (2018-2023)
5.1.3 North America Antidiabetic Biguanides Sales in Value by Country (2018-2023)
5.2 North America Antidiabetic Biguanides Forecasted Market Size by Country
5.2.1 North America Antidiabetic Biguanides Sales in Volume by Country (2024-2029)
5.2.2 North America Antidiabetic Biguanides Sales in Value by Country (2024-2029)
6 Europe Antidiabetic Biguanides by Country
6.1 Europe Antidiabetic Biguanides Historic Market Size by Country
6.1.1 Europe Antidiabetic Biguanides Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
6.1.2 Europe Antidiabetic Biguanides Sales in Volume by Country (2018-2023)
6.1.3 Europe Antidiabetic Biguanides Sales in Value by Country (2018-2023)
6.2 Europe Antidiabetic Biguanides Forecasted Market Size by Country
6.2.1 Europe Antidiabetic Biguanides Sales in Volume by Country (2024-2029)
6.2.2 Europe Antidiabetic Biguanides Sales in Value by Country (2024-2029)
7 Asia-Pacific Antidiabetic Biguanides by Region
7.1 Asia-Pacific Antidiabetic Biguanides Historic Market Size by Region
7.1.1 Asia-Pacific Antidiabetic Biguanides Market Size Growth Rate (CAGR) by Region: 2018 VS 2022 VS 2029
7.1.2 Asia-Pacific Antidiabetic Biguanides Sales in Volume by Region (2018-2023)
7.1.3 Asia-Pacific Antidiabetic Biguanides Sales in Value by Region (2018-2023)
7.2 Asia-Pacific Antidiabetic Biguanides Forecasted Market Size by Region
7.2.1 Asia-Pacific Antidiabetic Biguanides Sales in Volume by Region (2024-2029)
7.2.2 Asia-Pacific Antidiabetic Biguanides Sales in Value by Region (2024-2029)
8 Latin America Antidiabetic Biguanides by Country
8.1 Latin America Antidiabetic Biguanides Historic Market Size by Country
8.1.1 Latin America Antidiabetic Biguanides Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
8.1.2 Latin America Antidiabetic Biguanides Sales in Volume by Country (2018-2023)
8.1.3 Latin America Antidiabetic Biguanides Sales in Value by Country (2018-2023)
8.2 Latin America Antidiabetic Biguanides Forecasted Market Size by Country
8.2.1 Latin America Antidiabetic Biguanides Sales in Volume by Country (2024-2029)
8.2.2 Latin America Antidiabetic Biguanides Sales in Value by Country (2024-2029)
9 Middle East and Africa Antidiabetic Biguanides by Country
9.1 Middle East and Africa Antidiabetic Biguanides Historic Market Size by Country
9.1.1 Middle East and Africa Antidiabetic Biguanides Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
9.1.2 Middle East and Africa Antidiabetic Biguanides Sales in Volume by Country (2018-2023)
9.1.3 Middle East and Africa Antidiabetic Biguanides Sales in Value by Country (2018-2023)
9.2 Middle East and Africa Antidiabetic Biguanides Forecasted Market Size by Country
9.2.1 Middle East and Africa Antidiabetic Biguanides Sales in Volume by Country (2024-2029)
9.2.2 Middle East and Africa Antidiabetic Biguanides Sales in Value by Country (2024-2029)
10 Company Profiles
10.1 Pfizer
10.1.1 Pfizer Company Information
10.1.2 Pfizer Introduction and Business Overview
10.1.3 Pfizer Antidiabetic Biguanides Sales, Revenue and Gross Margin (2018-2023)
10.1.4 Pfizer Antidiabetic Biguanides Products Offered
10.1.5 Pfizer Recent Development
10.2 AstraZeneca
10.2.1 AstraZeneca Company Information
10.2.2 AstraZeneca Introduction and Business Overview
10.2.3 AstraZeneca Antidiabetic Biguanides Sales, Revenue and Gross Margin (2018-2023)
10.2.4 AstraZeneca Antidiabetic Biguanides Products Offered
10.2.5 AstraZeneca Recent Development
10.3 GlaxoSmithKline
10.3.1 GlaxoSmithKline Company Information
10.3.2 GlaxoSmithKline Introduction and Business Overview
10.3.3 GlaxoSmithKline Antidiabetic Biguanides Sales, Revenue and Gross Margin (2018-2023)
10.3.4 GlaxoSmithKline Antidiabetic Biguanides Products Offered
10.3.5 GlaxoSmithKline Recent Development
10.4 Merck & Co
10.4.1 Merck & Co Company Information
10.4.2 Merck & Co Introduction and Business Overview
10.4.3 Merck & Co Antidiabetic Biguanides Sales, Revenue and Gross Margin (2018-2023)
10.4.4 Merck & Co Antidiabetic Biguanides Products Offered
10.4.5 Merck & Co Recent Development
10.5 Eli Lilly
10.5.1 Eli Lilly Company Information
10.5.2 Eli Lilly Introduction and Business Overview
10.5.3 Eli Lilly Antidiabetic Biguanides Sales, Revenue and Gross Margin (2018-2023)
10.5.4 Eli Lilly Antidiabetic Biguanides Products Offered
10.5.5 Eli Lilly Recent Development
10.6 Sanofi
10.6.1 Sanofi Company Information
10.6.2 Sanofi Introduction and Business Overview
10.6.3 Sanofi Antidiabetic Biguanides Sales, Revenue and Gross Margin (2018-2023)
10.6.4 Sanofi Antidiabetic Biguanides Products Offered
10.6.5 Sanofi Recent Development
10.7 Takeda Pharmaceuticals
10.7.1 Takeda Pharmaceuticals Company Information
10.7.2 Takeda Pharmaceuticals Introduction and Business Overview
10.7.3 Takeda Pharmaceuticals Antidiabetic Biguanides Sales, Revenue and Gross Margin (2018-2023)
10.7.4 Takeda Pharmaceuticals Antidiabetic Biguanides Products Offered
10.7.5 Takeda Pharmaceuticals Recent Development
10.8 Novo Nordisk
10.8.1 Novo Nordisk Company Information
10.8.2 Novo Nordisk Introduction and Business Overview
10.8.3 Novo Nordisk Antidiabetic Biguanides Sales, Revenue and Gross Margin (2018-2023)
10.8.4 Novo Nordisk Antidiabetic Biguanides Products Offered
10.8.5 Novo Nordisk Recent Development
10.9 Servier Laboratories
10.9.1 Servier Laboratories Company Information
10.9.2 Servier Laboratories Introduction and Business Overview
10.9.3 Servier Laboratories Antidiabetic Biguanides Sales, Revenue and Gross Margin (2018-2023)
10.9.4 Servier Laboratories Antidiabetic Biguanides Products Offered
10.9.5 Servier Laboratories Recent Development
10.10 Boehringer Ingelheim
10.10.1 Boehringer Ingelheim Company Information
10.10.2 Boehringer Ingelheim Introduction and Business Overview
10.10.3 Boehringer Ingelheim Antidiabetic Biguanides Sales, Revenue and Gross Margin (2018-2023)
10.10.4 Boehringer Ingelheim Antidiabetic Biguanides Products Offered
10.10.5 Boehringer Ingelheim Recent Development
10.11 Bristol-Myers Squibb
10.11.1 Bristol-Myers Squibb Company Information
10.11.2 Bristol-Myers Squibb Introduction and Business Overview
10.11.3 Bristol-Myers Squibb Antidiabetic Biguanides Sales, Revenue and Gross Margin (2018-2023)
10.11.4 Bristol-Myers Squibb Antidiabetic Biguanides Products Offered
10.11.5 Bristol-Myers Squibb Recent Development
11 Upstream, Opportunities, Challenges, Risks and Influences Factors Analysis
11.1 Antidiabetic Biguanides Key Raw Materials
11.1.1 Key Raw Materials
11.1.2 Key Raw Materials Price
11.1.3 Raw Materials Key Suppliers
11.2 Manufacturing Cost Structure
11.2.1 Raw Materials
11.2.2 Labor Cost
11.2.3 Manufacturing Expenses
11.3 Antidiabetic Biguanides Industrial Chain Analysis
11.4 Antidiabetic Biguanides Market Dynamics
11.4.1 Antidiabetic Biguanides Industry Trends
11.4.2 Antidiabetic Biguanides Market Drivers
11.4.3 Antidiabetic Biguanides Market Challenges
11.4.4 Antidiabetic Biguanides Market Restraints
12 Market Strategy Analysis, Distributors
12.1 Sales Channel
12.2 Antidiabetic Biguanides Distributors
12.3 Antidiabetic Biguanides Downstream Customers
13 Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.2 Data Source
14.2 Author Details
14.3 Disclaimer
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
